Abstract: The embodiments of the present invention provide a crushing cavity structure for the technical field of crushing cavities of cone crushing equipment.

Abstract: The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.

Abstract: The present invention relates to a pharmaceutical composition, comprising Tecovirimat, cyclodextrin and an additive, and optionally a pharmaceutically acceptable excipient. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.

Abstract: The present invention relates to a protein particle with a poorly water-soluble drug encapsulated therein and a preparation method therefor. The preparation method comprises the following steps: i) dissolving a poorly water-soluble drug and a liquid solubilizer into a good solvent; ii) partially or fully removing said good solvent from the product of step i); iii) mixing the product of step ii) with a protein; and iv) dispersing the product of step iii) in a poor solvent. The preparation method is simple and is suitable for industrial production.

Abstract: An injectable pharmaceutical composition of a sulfonylurea drug and a preparation method thereof were described. The pharmaceutical composition contains a sulfonylurea drug, a cyclodextrin and an additive.

Abstract: The present disclosure discloses a multi-gradient structure-reinforced cone crusher and a design method of a lining plate thereof. The multi-gradient structure-reinforced cone crusher includes a movable cone and a fixed cone arranged around the movable cone, and a crushing cavity formed in the radial space between the fixed cone and the movable cone, the surfaces of the fixed cone and the movable cone that are opposite to each other are respectively provided with a fixed cone lining plate and a movable cone lining plate, the working faces of the fixed cone lining plate and the movable cone lining plate that face the crushing cavity are provided with multiple sets of cast-in alloy, which are different in at least one of distribution density, maximum size of exposed surface and shape of the cast-in alloy in a direction from the feed port to the discharge port.

Abstract: The embodiments of the present invention provide a crushing cavity structure for the technical field of crushing cavities of cone crushing equipment.

Abstract: The present invention relates to a protein particle with a poorly water-soluble drug encapsulated therein and a preparation method therefor. The preparation method comprises the following steps: i) dissolving a poorly water-soluble drug and a liquid solubilizer into a good solvent; ii) partially or fully removing said good solvent from the product of step i); iii) mixing the product of step ii) with a protein; and iv) dispersing the product of step iii) in a poor solvent. The preparation method is simple and is suitable for industrial production.

Abstract: The present disclosure relates to a multicast security control method and device based on DNS. The method includes: transmitting a DNS request message to a domain name server to acquire a multicast source DNS address list of an IPTV server; conducting address verification on a multicast data message according to the multicast source DNS address list and a locally maintained multicast address list after the multicast data message issued by the IPTV server is received; and conducting forwarding control on the multicast data message according to a verification result.

Abstract: An injectable pharmaceutical composition of a sulfonylurea drug and a preparation method thereof were described. The pharmaceutical composition contains a sulfonylurea drug, a cyclodextrin and an additive.

Abstract: The present invention relates to a pharmaceutical composition, comprising Tecovirimat, cyclodextrin and an additive, and optionally a pharmaceutically acceptable excipient. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.

Abstract: The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.

Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.

Abstract: The present disclosure relates to a multicast security control method and device based on DNS. The method includes: transmitting a DNS request message to a domain name server to acquire a multicast source DNS address list of an IPTV server; conducting address verification on a multicast data message according to the multicast source DNS address list and a locally maintained multicast address list after the multicast data message issued by the IPTV server is received; and conducting forwarding control on the multicast data message according to a verification result.

Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.

Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.

Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.

Abstract: A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.

Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.